EOM Pharmaceutical (IMUC) Stock Price, News & Analysis

Company Overview

Immunocellular Therapeutics, Ltd., a clinical-stage pharmaceutical company, focuses on the development of therapeutics and delivery technologies for the treatment of inflammatory conditions and ocular diseases. Its lead clinical asset is EOM613 solution, a peptide nucleic-acid solution with anti-inflammatory and pro-inflammatory effects on cytokines and chemokines for the treatment of cancer cachexia and rheumatoid arthritis. The company also develops EOM 147, an investigational, broad-spectrum aminosterol with an intracellular mechanism for the treatment of chronic and debilitating retinal diseases. Immunocellular Therapeutics, Ltd. was founded in 2020 and is headquartered in Montvale, New Jersey.

Key Stats

• Today's Range: $0.08 to $0.10
• 50-Day Range: $0.06 to $0.11
• 52-Week Range: $0.01 to $0.21
• Volume: 2,110 shs
• Average Volume: 5,807 shs
• Market Capitalization: $12.57 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

IMUC Stock Analysis - Frequently Asked Questions

How have IMUC shares performed this year?

EOM Pharmaceutical's stock was trading at $0.1688 on January 1st, 2025. Since then, IMUC stock has decreased by 41.1% and is now trading at $0.0994.

How were EOM Pharmaceutical's earnings last quarter?

EOM Pharmaceutical Holdings, Inc. (OTCMKTS:IMUC) announced its quarterly earnings data on Monday, August, 13th. The company reported ($0.01) earnings per share (EPS) for the quarter.

How do I buy shares of EOM Pharmaceutical?

Shares of IMUC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of EOM Pharmaceutical own?

Based on aggregate information from My MarketBeat watchlists, some other companies that EOM Pharmaceutical investors own include Argos Therapeutics (ARGSQ), Nightfood (NGTF), Meta Platforms (META), LadRx (CYTR), Inovio Pharmaceuticals (INO), MannKind (MNKD) and Agenus (AGEN).

Company Calendar

• Last Earnings: 8/13/2018
• Today: 8/21/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: MED - DRUGS
• Sub-Industry: Pharmaceutical Products
• Current Symbol: OTCMKTS:IMUC
• CIK: 822411
• Web: www.imuc.com
• Phone: (201) 351-0605
• Fax: 818-224-5287
• Employees: 3
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 126,500,000
• Free Float: 122,354,000
• Market Cap: $12.57 million
• Optionable: Not Optionable
• Beta: -0.01